Christopher Hillyer
President and Chief Executive Officer · New York Blood Center
Credentials: · ·
History
Present
Pathology-Anatomic and Clinical
University of Rochester School of Medicine
Trinity College
Research
Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants
eLife · 2020 · 1,094 citations
Neutralizing Antibodies against SARS-CoV-2 and Other Human Coronaviruses
Trends in Immunology · 2020 · 640 citations
Dose of prophylactic platelet transfusions and prevention of hemorrhage
New England Journal of Medicine · 2010 · 504 citations
38 papers
27 papers · 3 as a fellow
- CJ
23 papers
- JZ
15 papers
- EW
9 papers
- KH
9 papers
7 papers · 7 as a fellow
7 papers · 2 as a resident
Grants
- 2008–2013
Serious Hazards of Transfusion & Cellular Therapies: Mechanisms and Intervention
National Heart, Lung, and Blood Institute · P01
Contact PI · $2.7M · Emory University
- 2002–2012
Transfusion Medicine/Hemostasis Clinical Trails Network
National Heart, Lung, and Blood Institute · U01
Contact PI · $1.9M · Emory University
- 2004–2010
Retrovirus Epidemiology Donor Study-II (REDS-II) Blood Center
National Heart, Lung, and Blood Institute · N01
Contact PI · $449.3K · Emory University
- 2008–2009
Development of an ABO Incompatibility Stop Device (AISD)
National Heart, Lung, and Blood Institute · R41
Contact PI · $132.4K · Transfusion and Transplantation Tech
Clinical trials
- 2009–2010
Principal investigator · Terminated · Phase 3
Carelon Research
- 2006
Fresh-Frozen Plasma Infusions to Reduce Risk of Bleeding Related to Invasive Procedures
Principal investigator · Withdrawn · Phase 3
Massachusetts General Hospital
- 2004–2008
Optimal Platelet Dose Strategy for Management of Thrombocytopenia
Principal investigator · Completed · Phase 3
Carelon Research
- 2004–2009
Retrovirus Epidemiology Donor Study-II (REDS-II)
Completed
National Heart, Lung, and Blood Institute (NHLBI)